Preliminary Assessment of Sarcopenic Obesity Risk After Sleeve Gastrectomy Using Dual-Modality Imaging: A Six-Month MRI and DXA Pilot Study

Sarcopenic obesity represents a complex metabolic condition characterized by excess adiposity combined with skeletal muscle loss. In the context of bariatric surgery, accurately identifying this phenotype is critical because it influences long-term nutritional outcomes and recovery trajectories. However, the absence of standardized diagnostic criteria makes interpretation of muscle tissue changes after sleeve gastrectomy difficult, as different diagnostic indices can yield markedly different conclusions about the same patients.

This preliminary analysis from the SarxOb trial (NCT04617392) sought to evaluate the utility of dual-modality imaging in assessing body composition. Eleven female patients undergoing laparoscopic sleeve gastrectomy were prospectively followed for six months using magnetic resonance imaging and dual-energy X-ray absorptiometry. The study compared several body-composition indices to determine their sensitivity and specificity for detecting sarcopenic obesity risk in this specific surgical population.

The primary findings indicate a significant decrease in lean body mass over the six-month period. Lean body mass decreased from 56.3 ± 6.2 kg to 47.6 ± 6.0 kg (p < 0.05). This substantial reduction highlights the importance of precise measurement techniques, as variations in methodology could obscure these clinically relevant changes or lead to inconsistent risk stratification across different research settings.

The study demonstrates that dual-modality imaging provides complementary data for assessing body composition changes post-surgery. While MRI offers detailed soft tissue characterization, DXA remains a standard tool for bone mineral density and total body fat assessment. The combination of these modalities may improve diagnostic accuracy compared to single-modality approaches alone.

It is important to note that this study involved only eleven female patients, which limits the generalizability of findings to broader populations. Additionally, the preliminary nature of the analysis suggests further validation with larger cohorts is necessary before clinical implementation. These results should be interpreted as research-use only and do not constitute medical advice or product recommendations for laboratory peptide suppliers.